JPMorgan Maintains Buy Rating on Vera Therapeutics
JPMorgan analyst Anupam Rama has maintained a Buy rating on Vera Therapeutics with a price target of $75.
Stocks · News reference
Wedbush adjusted its price target for Vera Therapeutics from $34 to $29 while maintaining a neutral rating on the stock.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
JPMorgan analyst Anupam Rama has maintained a Buy rating on Vera Therapeutics with a price target of $75.
Vera Therapeutics granted stock options and restricted stock units to three new employees under its 2024 Inducement Plan.
Vera Therapeutics reported $10.3 million in net product revenue for the third quarter of 2026, driven by the early launch momentum of TRUTAKNA (atacicept-vymj).
Vera Therapeutics, Inc. announced that its management team will participate in a fireside chat and investor meetings at the upcoming Guggenheim 3rd Annual Healthcare Innovation Conference.
Leerink Partners analyst Will Soghikian initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Market Perform rating and announces Price Target of $34.